Pharmaceuticals News

The pharmaceuticals news email from Wiser has been specifically designed for anyone with an interest in the industry. This includes medical practitioners, investors and those involved in research and development. By its very nature, the pharmaceutical industry is subject to constant change. It is a research-driven industry with companies spending much of their revenues developing new medicines and vaccines. As a result patients are able to get new and more effective treatments. This is helping to increase the life expectancy of individuals in most countries. But there are challenges. The costs of the research and development can be large which puts up the price of drugs, while governments and the medical industry argue to try to keep prices as low as possible. The industry also faces challenges from alternatives, both legal (through generic drugs) and illegal (through black market economies). To follow the latest developments in this industry you should sign up for the pharmaceuticals news email from Wiser. It is the best way to find must-read articles on the topic from around the web.

Recent Pharmaceuticals News Coverage
 
Your Weekly Recommendations Tuesday, November 21, 2017
 
Recommended for you
Teva Pharmaceutical: Generidiculous!
Seeking Alpha • Pinxter Analytics
In US, More than One-Third Think Government and Business Leaders are Corrupt, Media Shrug
Health Care Renewal • Roy M. Poses Md
Is the NHS being taken for a ride on drug prices? We need to know | Nils Pratley
The Guardian • Nils Pratley
A key medicine agency has left Britain. This is the start of a Brexodus | Mike Galsworthy
The Guardian • Mike Galsworthy
UK pharma industry prepares for hard Brexit
Financial Times
Cytokinetics Pivots to Another ALS Drug After Phase 3 Failure
Xconomy • Frank Vinluan
HHS secretary nominee Alex Azar raked in millions as executive of pharma company Eli Lilly
FierceHealthcare • Paige Minemyer
New Div On The Block Quarterly Earnings Round-Up II: Part 2
Seeking Alpha
Economic Scene: Patent ‘Trolls’ Recede as Threat to Innovation. Will Justices Change That?
The New York Times • Eduardo Porter
Trump's choice for HHS secretary made millions off pharma
Politico • Dan Diamond
 
Recommended for You
Accounting, Finance
Teva Pharmaceutical: Generidiculous!
Seeking AlphaPinxter Analytics
Summary Sure, Teva's growth trajectory has stalled with exclusivity loss of Copaxone and a $6.1 billion impairment charge but 4.6x 2018 EPS estimates? Really? With some growth remaining even before any one of the company's 300 generic launches expected in 2018, trading...
Share
Health Care Costs, Health Care Industry
In US, More than One-Third Think Government and Business Leaders are Corrupt, Media Shrug
Health Care RenewalRoy M. Poses Md
We have noted (most recently here), that health care corruption, particularly its global nature and its presence in developed countries like the US, is a taboo topic and thus remains anechoic. Yet corruption in general, and health care corruption in particular, are...
Share
GlaxoSmithKline plc, Hedge Funds
Is the NHS being taken for a ride on drug prices? We need to know | Nils Pratley
The GuardianNils Pratley
The Competition and Markets Authority (CMA) has discovered a rich seam for inquiries – pharmaceutical companies allegedly gouging the National Health Service. Pfizer, together with a small UK company called Flynn Pharma, was fined £90m last December for “excessive and unfair” pricing...
Share
Pharmaceuticals
A key medicine agency has left Britain. This is the start of a Brexodus | Mike Galsworthy
The GuardianMike Galsworthy
Amsterdam has won the right to become the new host for the European Medicines Agency (EMA). In a nail-biting final round last night, the 19 European cities that had put in bids had been whittled down to Milan and Amsterdam, sharing an...
Share
Health Care Industry, Pharmaceuticals
UK pharma industry prepares for hard Brexit
Financial Times
Keep abreast of significant corporate, financial and political developments around the world. Stay informed and spot emerging risks and opportunities
Share
Pharmaceuticals, Sanofi SA
Cytokinetics Pivots to Another ALS Drug After Phase 3 Failure
XconomyFrank Vinluan
San Francisco — Cytokinetics’ bid to offer a new drug for amyotrophic lateral sclerosis (ALS) was dealt a setback after the company’s lead experimental treatment for the disease failed in a late-stage clinical trial. The results mean the end for tirasemtiv, one...
Share
Health Care Industry, Pharmaceuticals
HHS secretary nominee Alex Azar raked in millions as executive of pharma company Eli Lilly
FierceHealthcarePaige Minemyer
President Donald Trump's nominee to head the Department of Health Human Services earned millions as an executive at the pharmaceutical company Eli Lilly, newly released financial documents show. Alex Azar served in leadership roles at Eli Lilly for the better part of...
Share
Abbott Laboratories, Accounting
New Div On The Block Quarterly Earnings Round-Up II: Part 2
Seeking Alpha
Summary As we pass the middle of the final quarter of 2017, many companies have already reported their earnings results from the previous three months. Using earnings as a chance to review one's holdings helps justify the original investment thesis. I look...
Share
Copyright, Finance
Economic Scene: Patent ‘Trolls’ Recede as Threat to Innovation. Will Justices Change That?
The New York TimesEduardo Porter
In August, real estate agents in Texas fended off a company’s demands for royalty payments for a feature of many websites: the ability to show prospective home buyers where local schools, parks and grocery stores are. Administrative law judges at the United...
Share
GlaxoSmithKline plc, Pharmaceuticals
Trump's choice for HHS secretary made millions off pharma
PoliticoDan Diamond
AZAR MADE MILLIONS OFF PHARMA — HHS secretary nominee Alex Azar made nearly $2 million in his last year atop drug giant Eli Lilly’s U.S. arm before leaving in January. But since his departure, he’s continued to rake in the industry money,...
Share